Kumar, S., Harrison, S. J., Cavo, M., Rubia, J. D. E. L. A., Popat, R., Gasparetto, C. J., … Moreau, P. (2019). A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. In Clinical Lymphoma Myeloma and Leukemia (Vol. 19, pp. e31–e31). Elsevier BV. https://doi.org/10.1016/j.clml.2019.09.046

Kumar, Shaji, Simon J. Harrison, Michele Cavo, Javier D. E. L. A. Rubia, Rakesh Popat, Cristina J. Gasparetto, Vania Hungria, et al. “A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.” In Clinical Lymphoma Myeloma and Leukemia, 19:e31–e31. Elsevier BV, 2019. https://doi.org/10.1016/j.clml.2019.09.046.

Kumar S, Harrison SJ, Cavo M, Rubia JDELA, Popat R, Gasparetto CJ, et al. A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2019. p. e31–e31.

Kumar, Shaji, et al. “A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.” Clinical Lymphoma Myeloma and Leukemia, vol. 19, no. 10, Elsevier BV, 2019, pp. e31–e31. Crossref, doi:10.1016/j.clml.2019.09.046.

Kumar S, Harrison SJ, Cavo M, Rubia JDELA, Popat R, Gasparetto CJ, Hungria V, Salwender HJ, Suzuki K, Kim I, Punnoose E, Hong W-J, Freise KJ, Sood A, Jalaluddin M, Ross J, Ward JE, Maciag P, Moreau P. A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2019. p. e31–e31.